327 related articles for article (PubMed ID: 27706215)
21. Polyneuropathy in levodopa-treated Parkinson's patients.
Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
[TBL] [Abstract][Full Text] [Related]
22. Metabolic correlates of levodopa response in Parkinson's disease.
Feigin A; Fukuda M; Dhawan V; Przedborski S; Jackson-Lewis V; Mentis MJ; Moeller JR; Eidelberg D
Neurology; 2001 Dec; 57(11):2083-8. PubMed ID: 11739830
[TBL] [Abstract][Full Text] [Related]
23. Effects of levodopa therapy on voxel-based degree centrality in Parkinson's disease.
Zhong M; Yang W; Huang B; Jiang W; Zhang X; Liu X; Wang L; Wang J; Zhao L; Zhang Y; Liu Y; Lin J; Huang R
Brain Imaging Behav; 2019 Oct; 13(5):1202-1219. PubMed ID: 30091020
[TBL] [Abstract][Full Text] [Related]
24. Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT.
Contin M; Martinelli P; Riva R; Dondi M; Fanti S; Pettinato C; Scaglione C; Albani F; Baruzzi A
J Neurol; 2003 Dec; 250(12):1475-81. PubMed ID: 14673582
[TBL] [Abstract][Full Text] [Related]
25. A comparison of inhomogeneous magnetization transfer, myelin volume fraction, and diffusion tensor imaging measures in healthy children.
Geeraert BL; Lebel RM; Mah AC; Deoni SC; Alsop DC; Varma G; Lebel C
Neuroimage; 2018 Nov; 182():343-350. PubMed ID: 28916179
[TBL] [Abstract][Full Text] [Related]
26. Integrated robotics platform with haptic control differentiates subjects with Parkinson's disease from controls and quantifies the motor effects of levodopa.
Gaprielian P; Scott SH; Lowrey C; Reid S; Pari G; Levy R
J Neuroeng Rehabil; 2019 Oct; 16(1):124. PubMed ID: 31655612
[TBL] [Abstract][Full Text] [Related]
27. Regional volumetric change in Parkinson's disease with cognitive decline.
Gee M; Dukart J; Draganski B; Wayne Martin WR; Emery D; Camicioli R
J Neurol Sci; 2017 Feb; 373():88-94. PubMed ID: 28131236
[TBL] [Abstract][Full Text] [Related]
28. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
[TBL] [Abstract][Full Text] [Related]
29. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
30. Integrated PET/MRI With
Wu Y; Xu XJ; Sun X; Zhai H; Wang T; Cao XB; Xu Y
Behav Brain Res; 2023 Oct; 454():114609. PubMed ID: 37532003
[TBL] [Abstract][Full Text] [Related]
31. Microstructural and functional alterations of the ventral pallidum are associated with levodopa-induced dyskinesia in Parkinson's disease.
Gan Y; Su D; Zhang Z; Zhang Z; Yan R; Liu Z; Wang Z; Zhou J; Lam JST; Wu T; Jing J; Feng T
Eur J Neurol; 2024 Feb; 31(2):e16147. PubMed ID: 37975786
[TBL] [Abstract][Full Text] [Related]
32. Sex effects on brain structure in de novo Parkinson's disease: a multimodal neuroimaging study.
Tremblay C; Abbasi N; Zeighami Y; Yau Y; Dadar M; Rahayel S; Dagher A
Brain; 2020 Oct; 143(10):3052-3066. PubMed ID: 32980872
[TBL] [Abstract][Full Text] [Related]
33. Amplitude of low-frequency oscillations in Parkinson's disease: a 2-year longitudinal resting-state functional magnetic resonance imaging study.
Hu XF; Zhang JQ; Jiang XM; Zhou CY; Wei LQ; Yin XT; Li J; Zhang YL; Wang J
Chin Med J (Engl); 2015 Mar; 128(5):593-601. PubMed ID: 25698189
[TBL] [Abstract][Full Text] [Related]
34. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
[TBL] [Abstract][Full Text] [Related]
35. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
36. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
Imamura K; Okayasu N; Nagatsu T
Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269
[TBL] [Abstract][Full Text] [Related]
37. Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease.
Al-Bachari S; Parkes LM; Vidyasagar R; Hanby MF; Tharaken V; Leroi I; Emsley HC
Neuroimage Clin; 2014; 6():1-8. PubMed ID: 25379411
[TBL] [Abstract][Full Text] [Related]
38. Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study.
Cao C; Li D; Zeng K; Zhan S; Huang P; Li X; Sun B
Clin EEG Neurosci; 2019 Mar; 50(2):134-140. PubMed ID: 29914268
[No Abstract] [Full Text] [Related]
39. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
40. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
